Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2017-06-02 Director's Dealing
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2017-06-02 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2017, reporting the results of the 2017 Annual Meeting of Shareholders of Xenon Pharmaceuticals Inc. It details the voting results on three proposals: election of directors, appointment of independent auditors, and authorization of audit committee remuneration. The content focuses on the official results of shareholder votes at the AGM. The document length is 4362 characters, which is relatively short but contains detailed voting results, not just an announcement of a report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-06-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-05-16 English
10-Q
Interim / Quarterly Report Q1 2017
2017-05-09 English
8-K - Q1 EARNINGS RELEASE
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing dated May 9, 2017, from Xenon Pharmaceuticals Inc. It announces the company's financial results for the three-month period ended March 31, 2017, via a press release attached as Exhibit 99.1. The text explicitly states that the information is furnished but not filed with the SEC, and the document itself is short (3358 characters). It is an announcement of the earnings release rather than the earnings release report itself. According to the 'Menu vs Meal' rule, such a short document announcing a report is classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER).
2017-05-09 English
XENE-DEF14A-2017
Proxy Solicitation & Information Statement
2017-04-27 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.